Compare Summit Therapeutics Inc (SMMT) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs TKO Group Holdings Inc — how do they compare? Summit Therapeutics Inc trades at $17.4 (market cap $13.71B), while TKO Group Holdings Inc trades at $179.25 (market cap $13.28B). The key difference: Summit Therapeutics Inc and TKO Group Holdings Inc are close in size by market cap, and TKO Group Holdings Inc pays a 1.74% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and TKO Group Holdings Inc for 30 Days on average.
| SMMT | TKO | |
|---|---|---|
Market Cap | $13.71B | $13.28B |
Volume | 6,173,057 | 857,653 |
Sector | Health | Media |
52-Week High | $26.38 | $224.96 |
52-Week Low | $12.43 | $175.58 |
Typical Hold Time | 16 Days | 30 Days |
Enterprise Value | $13.04B | $17.64B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
TKO trades at $181.54, up 1.62% on the day, but technical indicators signal a bearish trend. The company reported mixed Q2 2026 earnings, missing EPS estimates but beating on revenue, and raised full-year guidance. Strong analyst sentiment persists with an 89% buy rating and a $227 consensus price target, suggesting significant upside. Recent news highlights media rights strength and a declared dividend.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but risks include execution on guidance and competitive pressures. The stock's high P/E of 63.73 indicates premium valuation, requiring sustained growth to justify. Near-term price action may be influenced by technical resistance and Q3 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
